Technetium (99mTc) tilmanocept

Technetium (^99mTc) tilmanocept

Systematic (IUPAC) name
Dextran 3-[(2-aminoethyl)thio]propyl 17-carboxy-10,13,16-tris(carboxymethyl)-8-oxo-4-thia-7,10,13,16-tetraazaheptadec-1-yl 3-[[2-[[1-imino-2-(D-mannopyranosylthio)ethyl]amino]ethyl]thio]propyl ether technetium-99m complexes
Clinical data
Trade names	Lymphoseek
AHFS/Drugs.com	entry
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	Intradermal, subcutaneous
Pharmacokinetic data
Biological half-life	1.75 to 3.05 hours at injection site
Identifiers
ATC code	V09IA09
Chemical data
Formula	(C6H10O5)n(C19H28N4O9S^99mTc)3–8(C13H24N2O5S2)12–20(C5H11NS)0–17
Molar mass	15,281–23,454 g/mol[1]

Technetium (^99mTc) tilmanocept, trade name Lymphoseek, is a radiopharmaceutical diagnostic imaging agent approved by the U.S. Food and Drug Administration (FDA) for the imaging of lymph nodes.^[1][2] It is used to locate those lymph nodes which may be draining from tumors, and assist doctors in locating those lymph nodes for removal during surgery.^[3]

References

1. FDA Professional Drug Information
2. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm343525.htm
3. Marcinow, A. M.; Hall, N.; Byrum, E.; Teknos, T. N.; Old, M. O.; Agrawal, A. (2013). "Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: Initial institutional report in an ongoing phase 3 study". JAMA otolaryngology-- head & neck surgery 139 (9): 895–902. doi:10.1001/jamaoto.2013.4239. PMID 24051744.